Characteristics of patients according to treatment with lipid lowering agents and lipaemic status
| Total population (n = 342) | Patients with dyslipaemia treated with LLAs (n = 129) | Patients with untreated dyslipaemia (n = 105) | Normolipaemic patients (n = 108) | p Value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Values are n (%). | ||||||||||
| AChEI, acetyl choline esterase inhibitor; DRS, dementia rating scale26; LLA, lipid lowering agent; MMSE, mini-mental state examination; NA, not available; SSRI, selective serotonin reuptake inhibitor. | ||||||||||
| Men | 110 (32.2) | 46 (35.7) | 25 (23.8) | 39 (36.1) | 0.088 | |||||
| Age (years) at the end of the study | 76.5 (7.5) | 75.3 (7.1) | 76.9 (7.3) | 77.5 (8.0) | 0.065 | |||||
| Arterial hypertension | 197 (57.6) | 72 (55.8) | 59 (56.2) | 66 (61.1) | 0.783 | |||||
| Diabetes mellitus | 56 (16.4) | 25 (19.4) | 12 (11.4) | 19 (17.6) | 0.241 | |||||
| Dyslipaemia | 234 (68.4) | 129 (100) | 105 (100) | 0 | <0.0001 | |||||
| Hypercholesterolaemia | 213 (62.3) | 124 (96.1) | 89 (84.8) | 0 | <0.0001 | |||||
| Hypertriglyceridaemia | 76 (22.2) | 32 (24.8) | 44 (41.9) | 0 | <0.0001 | |||||
| Small vascular lesions on imaging | 85 (24.9) | 27 (24.8) | 22 (21) | 36 (33.3) | 0.048 | |||||
| Duration of disease at entry | 35.8 (89.8) | 32.9 (24) | 47.4 (111.2) | 27.9 (113.1) | 0.258 | |||||
| MMSE score at entry | 21.3 (5.1) | 22.2 (5.1) | 21 (5.1) | 20.5 (5.1) | 0.034 | |||||
| DRS score at entry | 112 (19.2), NA = 37 | 116.4 (16.2), NA = 11 | 109.7 (21.8), NA = 9 | 108.6 (19.1), NA = 17 | 0.006 | |||||
| AChEI at entry: | 279 (81.6) | 104 (80.6) | 87 (82.9) | 88 (81.5%) | 0.908 | |||||
| Treatment with AChEI (end of follow up) | 229 (67.0), NA = 23 | 90 (69.8), NA = 7 | 63 (60.0), NA = 15 | 78 (72.2), NA = 1 | 0.012 | |||||
| Total duration of AChEIs (months) | 21.8 (16), NA = 10 | 23.3 (16.8) NA = 4 | 22.5 (16.7), NA = 3 | 19.4 (14), NA = 3 | 0.237 | |||||
| Antidepressant (SSRI) | 158 (46.2) | 57 (44.2) | 57 (54.3) | 44 (40.7) | 0.118 | |||||
| Follow up duration (months) | 34.8 (18.9) | 37.1 (21.5) | 35.5 (18) | 31.3 (16) | 0.053 | |||||
| Delay between first and last MMSE scores (months) | 30.9 (17.7) | 33.6 (20) | 31.6 (16.2) | 27.1 (15.3) | 0.017 | |||||
| Annual decline on MMSE score | 2.1 (2.8) | 1.5 (2.5) | 2.4 (2.6) | 2.6 (3.3) | 0.010 | |||||
| Follow up duration (months) | 34.8 (18.9) | 37.1 (21.5) | 35.5 (18) | 31.3 (16) | 0.053 | |||||
| Death | 35 (10.2) | 13 (10.1) | 11 (10.5) | 11 (10.2) | 0.995 | |||||